Value investing is experiencing a resurgence as value stocks outperform growth stocks after several challenging years. Bill Smead, co-manager of the Smead Value Fund, has positioned his portfolio to capitalize on this shift, with the fund up 6.75% this year and outperforming 97% of similar funds over the past 15…

Oncology investments remain a focal point for pharmaceutical investors as the sector continues to generate substantial returns despite growing competition from newer therapeutic areas. While mid-cap biotech company ImmunityBio has captured significant attention following its recent share price surge and impressive revenue growth driven by its newly approved bladder cancer…

Netflix has officially withdrawn from its bid to acquire Warner Bros. Discovery’s entertainment assets, clearing the way for Paramount Skydance to complete the deal. According to a statement from Netflix, Warner Bros.’ board of directors determined that Paramount’s enhanced offer represented a “superior proposal,” and the streaming giant confirmed it…

Small-cap stocks and emerging markets are capturing renewed investor attention as market dynamics shift in early 2024, according to recent financial analysis. Portfolio managers and institutional investors are increasingly allocating capital toward these historically volatile asset classes, seeking higher growth potential amid changing global economic conditions. The strategic pivot reflects…